STAAR Surgical price target lowered to $38 from $43 at Canaccord

Canaccord analyst Jason Mills lowered his price target for STAAR Surgical to $38 from $43, saying he recommends adding to positions, notwithstanding the uncertainty around the timing of EVO ICL approval in the U.S. Mills tells investors in a research note that he came away from a meeting with ophthalmologists, industry consultants and STAAR management at the American Society of Cataract & Refractive Surgeons meeting this weekend “confident” in the firm’s near- and long-term ICL growth potential. Mills maintains a Buy rating.
https://thefly.com/landingPageNews.php?id=2903587